You are here

ANTIBODY HETEROCONJUGATES FOR TREATMENT OF SIV INFECTION

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 16311
Amount: $49,984.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1991
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
One Kendall Square
Cambridge, MA 02139
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Higgins, Paul J
 Principal Investigator
 (617) 225-6000
Business Contact
 1 R43 AI31712-01
Phone: () -
Research Institution
N/A
Abstract

THE GOAL OF THIS PROJECT IS TO GENERATE AND CHARACTERIZE A BISPECIFIC HETEROCONJUGATE ANTIBODY CAPABLE OF INDUCING THE CYTOLYSIS OF SIV-INFECTED CELLS. THE APPROACH IN PHASE I STUDY WILL ENTAIL CONJUGATING AN ANTI-CD3 MONOCLONAL ANTIBODY WITH AN ANTIBODY SPECIFIC FOR RECOMBINANT SIV ENVELOPE GLYCOPROTEIN GPL40. THE CYTOTOXIC ACTIVITY WILL BE TESTED IN AN IN VITRO SYSTEM USING CELLS INFECTED WITH RECOMBINANT VACCINIA VIRUS WHICH EXPRESS THE SIV ENV GENE AS TARGETS AND A HUMAN CTL LINE AS EFFECTORS. PHASE II STUDY WILL INVOLVE TESTING THE HETEROCONJUGATE IN VITRO AGAINST SIV-INFECTED CELLS USING CTL FROM SIV-INFECTED MACAQUES AS EFFECTORS. IN ADDITION, THE ABILITY OF THE ANTI-SIV HETEROCONJUGATE TO SUPPRESS VIRUS AND PREVENT DISEASE IN INFECTED MACAQUES WILL BE ASSESSED. THE DEVELOPMENT AND IN VIVO TESTING OF THE ANTI-SIV HETEROCONJUGATE WOULD PROVIDE AN EXCELLENT MEANS OF EVALUATING THIS TYPE ON IMMUNOTHERAPY FOR THE CLINICAL TREATMENT OF HIV-INFECTED HUMANS.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government